New data concerning the management of autoimmune liver diseases have emerged since the last single-topic meeting sponsored by the Brazilian Society of Hepatology to draw recommendations about the diagnosis and treatment of autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), overlap syndromes of AIH, PBC and PSC and specific complications and topics concerning AIH and cholestatic liver diseases. This manuscript updates those previous recommendations according to the best evidence available in the literature up to now. The same panel of experts that took part in the first consensus document reviewed all recommendations, which were subsequently scrutinized by all members of the Brazilian Society of Hepatology using a web-based approach. The updated recommendations are presented in the present manuscript.
INTRODUCTION
The Brazilian Society of Hepatology published evidence-based recommendations for the management of autoimmune liver diseases (ALD) in December 2015 issue of Archives of Gastroenterology, following a consensus meeting held in São Paulo on October 18th, 2014 (1) . The first version covered diagnosis and treatment of autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC) and their overlap syndromes; the management of specific complications of cholestasis, such as pruritus, fatigue and hypercolesterolemia and special controversial topics including management of recurrent cholangitis, prevention and management of biliary tract tumors in PSC and liver transplantation (LT) for AIH, PSC and PBC. Since then, a bulk of data concerning the diagnosis and treatment of ALD have emerged in the medical literature and even primary biliary cirrhosis have been properly renamed as primary biliary cholangitis (2) . Due to these reasons, the Brazilian Society of Hepatology sponsored another meeting in December 2018 to update the aforementioned recommendations. An organizing committee of five experts, the same who took part in the 1 rst consensus meeting submitted to the previous panel all topics to be reviewed according to the best-evidence available in literature using MEDLINE. All updated recommendations were discussed by the organizing committee and were further scrutinized by all members of the Brazilian Society of Hepatology using a web-based approach. Most of those updated recommendations were based on new data published since 2015 , which are briefly summarized in figures 1 to 4. The present manuscripts is the final version of the document followed by the recommendations, which were graded according to the grading system adopted by the American College of Cardiology and the American Heart Association, as outlined below (3): -Class I: conditions for which there is evidence and/or general agreement that a given diagnostic evaluation, procedure or treatment is beneficial, useful, and effective.
-Class II: conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a diagnostic evaluation, procedure or treatment.
-Class IIa: weight of evidence/opinion is in favor of usefulness/efficacy.
-Class IIb: usefulness/efficacy is less well established by evidence/opinion.
-Class III: conditions for which there is evidence and/or general agreement that a diagnostic evaluation, procedure/treatment is not useful/effective and in some cases may be harmful.
UPDATE OF RECOMMENDATIONS

I. AUTOIMMUNE HEPATITIS
Ia. AIH: Clinical manifestations 1. AIH primarily affects women in a 4:1 ratio, mostly in 5 to 25 years of age, but it can occur in all age and races. In the majority of cases, patients with AIH have unrecognized chronic liver disease with acute hepatitis-like symptoms, but signs and symptoms of advanced chronic liver disease may also be present. Less frequently, the disease can be present without symptoms or with fulminant hepatic failure (FHF).
Consequently its diagnosis should be considered in any patients with liver disease at any age (Class IIa). specific antigens, such as ELISA, immunoblotting or immunodiffusion.
(Class I) 6 . If anti-SLA testing is not possible, anti-SSA/Ro seropositivity can be considered an indirect evidence of anti-SLA/LP reactivity, since more than 70% of patients have concomitant reactivity. (Class IIa) 7. The revised International AIH Group (IAIHG) scoring system and the simplified AIH criteria can be used for the diagnosis of AIH, but the former performs better in the diagnostic evaluation of atypical cases (Class IIa). For pediatric patients with AIH, it is important to perform magnetic resonance cholangiopancreatography (MRCP) to exclude autoimmune sclerosing cholangitis, which is very common in this age group (Class IIa). However, it may de needed to assess the presence of PSC with features of AIH, in those subjects with disproportionally higher aminotransferases levels more than 5 times the upper limit of normal (Class Ib). 
4.
There is no sufficient evidence to recommend the use of fibrates or other pharmacological alternatives as specific therapies for PSC (Class IIb).
Immunosuppression with corticosteroids alone or in
combination with azathioprine is recommended in cases of PSC with AIH-like characteristics and for the treatment of PSC associated IgG4 (Class I).
6. There is no evidence that the use of UDCA reduces the risk of developing colon cancer or gallbladder cancer inpatients with PSC (Class III).
7. Pregnancy is generally well tolerated in women with compensated PSC, but there seems to be an increased risk of preterm birth (Class II). The use of UDCA can be considered during pregnancy, preferably after the first quarter (Class II). 3. Antibiotic prophylaxis should be given to those patients with PSC or with any other disease associated with biliary obstruction submitted to ERC in order to prevent cholangitis, particularly in the presence of inadequate biliary drainage (Class IIa). 
IIc. PSC: Endoscopic
VIIIb. Screening of liver and biliary tract cancer
LT may be warranted in those patients with decompensation of liver
disease due to flares of AIH due to poor adherence or spontaneous disease reactivation. In those cases, drug adjustments should be initially employed with concern due to the higher risk for development The indication of liver transplantation due to fatigue in CBP is still controversial, since fatigue does not
